pubmed.ncbi.nlm.nih.gov

Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation - PubMed

Multicenter Study

. 2020 Dec;43(12):1388-1397.

doi: 10.1002/clc.23448. Epub 2020 Aug 30.

Affiliations

Multicenter Study

Is race or ethnicity associated with under-utilization of statins among women in the United States: The study of women's health across the nation

Elizabeth A Jackson et al. Clin Cardiol. 2020 Dec.

Abstract

Background: Rates of statin use among minority women are unclear.

Hypothesis: We hypothesized that statin use would vary by race/ethnicity with lower rates among minority women compared with Whites.

Methods: Data from the study of women's health across the nation, a multiethnic cohort of women collected between 2009 to 2011 were used to examine reported statin use by race/ethnicity and risk profile. Multivariable logistic modeling was performed to estimate the odds ratio (OR) of statin treatment.

Results: Of the 2399 women included, 234 had a diagnosis of atherosclerotic disease (ASCVD), 254 were diabetic (without ASCVD), 163 had an LDL ≥190 mg/dL, and 151 had a 10 year ASCVD pooled risk score ≥7.5%. Statins were used by 49.6% of women with CVD; 59.8% of women with diabetes without known ASCVD; 42.3% of women with an LDL ≥190 mg/dL; and 19.9% of women with an ASCVD risk ≥7.5%. Rates of statin use were 43.8% for women with ≥ two prior ASCVD events and 69.4% for women with ≥ one prior ASCVD event plus multiple high-risk conditions. Among women eligible for statins, Black women had a significantly reduced adjusted odds of being on a statin (OR 0.53, 95% confidence interval [CI] 0.36-0.78) compared with White women.

Conclusions: In this cohort of multiethnic women, rates of statin use among women who would benefit were low, with Black women having lower odds of statin use than White women.

Keywords: cardiovascular prevention; race/ethnicity; statin therapy; women.

© 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1

SWAN participants by statin eligibility: consort diagram. SWAN, study of women's health across the nation

Similar articles

Cited by

References

    1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke Statistics‐2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139‐e596. - PubMed
    1. Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd‐Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012;308(17):1795‐1801. - PMC - PubMed
    1. Force USPST, Bibbins‐Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316(19):1997‐2007. - PubMed
    1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart protection study collaborative G. MRC/BHF heart protection study of cholesterol‐lowering with simvastatin in 5963 people with diabetes: a randomised placebo‐controlled trial. Lancet. 2003;361(9374):2005‐2016. - PubMed
    1. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care . The antihypertensive and lipid‐lowering treatment to prevent heart attack trial (ALLHAT‐LLT). JAMA. 2002;288(23):2998‐3007. - PubMed

Publication types

MeSH terms

Substances